Your search for non small cell lung cancer returned 4 results

Cancer patients with biomarker-positive tumors have better outcomes on immune checkpoint inhibitor therapy, a meta-analysis suggests.

Gavreto is an oral tyrosine kinase inhibitor.

Pemrydi RTU is expected to be available in the first quarter of 2024.

A regulatory decision is expected on November 27, 2023.